ImmuCell (ICCC)
(Real Time Quote from BATS)
$3.66 USD
+0.06 (1.67%)
Updated Sep 23, 2024 11:30 AM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for ImmuCell Corporation falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1 | 6 | 10 | 8 | 9 |
Receivables | 2 | 2 | 3 | 2 | 2 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 8 | 6 | 3 | 2 | 3 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 |
Total Current Assets | 11 | 14 | 16 | 12 | 13 |
Net Property & Equipment | 28 | 28 | 27 | 27 | 25 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 44 | 45 | 44 | 40 | 39 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 2 | 2 | 1 | 1 |
Current Portion Long-Term Debt | 1 | 1 | 1 | 1 | 1 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 4 | 3 | 3 | 2 | 3 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 11 | 9 | 8 | 9 | 7 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 19 | 14 | 12 | 12 | 10 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 1 |
Capital Surplus | 36 | 36 | 36 | 31 | 31 |
Retained Earnings | -12 | -6 | -4 | -4 | -3 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 25 | 30 | 33 | 28 | 29 |
Total Liabilities & Shareholder's Equity | 44 | 45 | 44 | 40 | 39 |
Total Common Equity | 25 | 30 | 33 | 28 | 29 |
Shares Outstanding | 7.70 | 7.70 | 7.70 | 7.20 | 7.20 |
Book Value Per Share | 3.25 | 3.95 | 4.23 | 3.93 | 4.03 |
Fiscal Year End for ImmuCell Corporation falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1 | 1 | 1 | 2 | 1 |
Receivables | 2 | 3 | 2 | 2 | 2 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 7 | 7 | 8 | 7 | 8 |
Other Current Assets | 0 | 1 | 0 | 1 | 0 |
Total Current Assets | 11 | 11 | 11 | 12 | 11 |
Net Property & Equipment | 26 | 27 | 28 | 28 | 29 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 42 | 43 | 44 | 45 | 44 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 2 | 2 | 2 | 2 |
Current Portion Long-Term Debt | 1 | 1 | 1 | 1 | 2 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 5 | 4 | 4 | 3 | 4 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 10 | 10 | 11 | 11 | 9 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 18 | 18 | 19 | 19 | 17 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 1 |
Capital Surplus | 37 | 36 | 36 | 36 | 36 |
Retained Earnings | -14 | -12 | -12 | -11 | -10 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 23 | 25 | 25 | 26 | 27 |
Total Liabilities & Shareholder's Equity | 42 | 43 | 44 | 45 | 44 |
Total Common Equity | 23 | 25 | 25 | 26 | 27 |
Shares Outstanding | 7.80 | 7.80 | 7.70 | 7.70 | 7.70 |
Book Value Per Share | 3.01 | 3.16 | 3.25 | 3.38 | 3.49 |